Key Stats for Gilead Stock
- 52-Week Range: $95 to $157
- Current Price: $129
- Street Mean Target: $158
- Street High Target: $180
- TIKR Model Target (Dec. 2030): $164
What Happened?
Gilead Sciences (GILD) is a biopharmaceutical company best known for its dominant HIV franchise, which generated $20.8 billion in revenue in 2025 and accounts for roughly 70% of the company’s total product sales.
That HIV franchise delivered 6% growth in 2025, and the number that changes the forward picture is $800 million: Gilead’s guidance for Yeztugo, its twice-yearly HIV prevention injectable, this year alone, up from $150 million in 2025.
Yeztugo is not a line extension on a legacy drug; it is a structurally different product designed to expand HIV prevention beyond the oral PrEP market entirely.
The coverage milestone arrived faster than anyone modeled, with Gilead hitting 90% payer coverage in under six months and approximately 90% of covered individuals accessing the drug at zero co-pay.
Beyond HIV, Gilead is preparing for up to four commercial launches in 2026, including Trodelvy in first-line metastatic triple-negative breast cancer, anito-cel (a BCMA CAR-T therapy targeting the $20 billion multiple myeloma market), a new once-daily bictegravir plus lenacapavir HIV treatment combination, and bulevirtide for chronic hepatitis D.
To fortify the pipeline heading into the 2030s, Gilead executed three acquisitions in rapid succession: Arcellx for approximately $7.8 billion, Ouro Medicines for up to $2.18 billion (co-funded 50% with Galapagos), and Tubulis for up to $5 billion, adding an antibody-drug conjugate platform with a lead asset in platinum-resistant ovarian cancer that posted a 50% confirmed overall response rate in Phase I.
CEO Daniel O’Day described the sequencing plainly on the Q4 call: “With many of the policy-related uncertainties behind us and no major product LOEs until 2036, Gilead is entering 2026 in a position of strength.”
The stock nonetheless sits 18% below its 52-week high, reflecting investor uncertainty about acquisition integration costs and whether Yeztugo can sustain its early momentum through a persistency curve that has yet to be fully established.
Q1 2026 results are scheduled for May 7, when management will provide the first detailed update on Yeztugo’s trajectory and early launch commentary on anito-cel preparation.
Wall Street’s Take on GILD Stock
Gilead stock’s HIV dominance has historically been understood. What the market has been slower to price is the simultaneous expansion into oncology, the speed of the Yeztugo build, and what a post-Arcellx, post-Tubulis pipeline looks like at full capacity.
With three acquisitions closing simultaneously and four product launches on the 2026 schedule, the market has fixated on near-term integration costs rather than the EBITDA compounding that sits underneath:
GILD’s EBITDA recovered sharply to $15.95 billion in 2025, up 41% year-over-year from a depressed $11.29 billion base, with consensus projecting the compounding continues toward around $17 billion in 2026 and around $18 billion in 2027.
Of 30 analysts covering Gilead Sciences stock with active opinions, 17 rate it a buy, 5 outperform, and 8 hold, with no sells on record; the mean price target of $158.36 implies around 23% upside from the current price, while the Street high sits at $180, anchored by analysts modeling full Yeztugo adoption and anito-cel multiple myeloma penetration.
Truist raised its price target to $155 from $152 in April, maintaining a buy rating, citing expectations for in-line Q1 results and flagging anito-cel’s December 2026 PDUFA date as the next major catalyst.
Trading at roughly 16x forward EBITDA against a peer group trading at 18 to 20x, and with EBITDA margins expanding from 39.3% in 2024 back toward a mid-50s baseline the company held through 2022, Gilead Sciences stock appears undervalued for a platform that has five Phase III readouts scheduled in 2026 and no patent cliff until 2036.
The core risk is acquisition-driven: with Arcellx, Ouro, and Tubulis all closing in Q2 2026, integration complexity is real, and IPR&D charges will weigh on GAAP earnings through the year; if any of the three programs disappoints in early clinical updates, the pipeline premium could erode faster than the core HIV franchise can offset.
The May 7 earnings call is the first place to watch: Yeztugo’s persistency data (the refill rate for the second injection) and anito-cel BLA acceptance confirmation are the two numbers that will tell investors whether the 2026 thesis is tracking or beginning to slip.
What Does the Valuation Model Say?
TIKR’s mid-case model prices Gilead Sciences stock at around $164 today, built on a revenue CAGR of around 5% through 2030 and net income margins expanding toward around 41%, a scenario directly supported by the Yeztugo ramp, the Biktarvy base, and four additional launches expected before year-end.
At around 16x forward EBITDA against consensus estimates projecting around $17 billion in 2026 EBITDA, and with EBITDA margins set to surpass 54% this year on course toward 58% by 2029, Gilead Sciences stock is undervalued for what the pipeline is about to deliver across HIV prevention, oncology, and inflammation.
The investment case hinges on a single question: whether the Yeztugo persistency curve, the anito-cel launch ramp, and the Tubulis ADC platform can compound returns fast enough to justify the acquisition costs Gilead has now committed.
What Has to Go Right
- Yeztugo persistency rates exceed the 50% injectable benchmark management cited, validating the $800 million 2026 guide and setting up $1.5 billion-plus in 2027
- Anito-cel receives FDA approval at the December 2026 PDUFA date with a label covering fourth-line-plus multiple myeloma, opening a $3.5 billion addressable market in year one
- TUB-040 Phase II data in platinum-resistant ovarian cancer confirms the 50% response rate seen in Phase I across 46 patients, unlocking registrational trial entry in 2027
- EBITDA margins hold above 54% in 2026 as HIV operating leverage offsets new launch investments, consistent with CFO Andy Dickinson’s guidance for $13.8 to $14.3 billion operating income
- The IDEAL Phase III trial for Livdelzi in incomplete PBC responders reads out positively in the second half of 2026, doubling the addressable patient population in a franchise already holding over 50% market share in second-line PBC
What Could Go Wrong
- Yeztugo refill rates disappoint on the May 7 call, revealing logistics friction in the injectable rollout that slows the multi-year build the $800 million guide assumes
- Arcellx, Ouro, and Tubulis integration costs run above the “modest and manageable” dollar increase to R&D that Dickinson guided, compressing 2026 EPS toward the low end of the $8.45 to $8.85 range
- A competitor BCMA CAR-T claims best-in-class safety parity with anito-cel ahead of the PDUFA date, reducing the pricing premium Kite is counting on to capture the $20 billion market-leader opportunity
- Phase III EVOKE-03 data for Trodelvy in first-line PD-L1 high non-small cell lung cancer disappoints, removing what management described as “a much larger market expansion opportunity” from the near-term revenue bridge
Should You Invest in Gilead Sciences, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up GILD stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Gilead Sciences, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze GILD stock on TIKR for Free →
